Loop Diuretics in the Treatment of Hypertension
- 作者:Line Malha ; Samuel J. Mann
- 关键词:Hypertension ; Diuretics ; Loop diuretics ; Torsemide ; Furosemide
- 刊名:Current Hypertension Reports
- 出版年:2016
- 出版时间:April 2016
- 年:2016
- 卷:18
- 期:4
- 全文大小:357 KB
- 参考文献:1.Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206–52. doi:10.1161/01.HYP.0000107251.49515.c2 .CrossRef PubMed
2.•
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20. doi:10.1001/jama.2013.284427 . Current North American guidelines for the treatment of hypertension.CrossRef PubMed
3.•
Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–219. doi:10.1093/eurheartj/eht15110.1093/eurheartj/eht151 . Current European guidelines for the treatment of hypertension.CrossRef PubMed
4.Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105–87. doi:10.1097/HJH.0b013e3281fc975a .CrossRef PubMed
5.Tamargo J, Segura J, Ruilope LM. Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. Expert Opin Pharmacother. 2014;15(5):605–21. doi:10.1517/14656566.2014.879117 .CrossRef PubMed
6.Ernst ME, Moser M. Use of diuretics in patients with hypertension. N Engl J Med. 2009;361(22):2153–64. doi:10.1056/NEJMra0907219 .CrossRef PubMed
7.Tu W, Pratt JH. A consideration of genetic mechanisms behind the development of hypertension in blacks. Curr Hypertens Rep. 2013;15(2):108–13. doi:10.1007/s11906-013-0332-9 .CrossRef PubMed PubMedCentral
8.Chun TY, Bankir L, Eckert GJ, Bichet DG, Saha C, Zaidi SA, et al. Ethnic differences in renal responses to furosemide. Hypertension. 2008;52(2):241–8. doi:10.1161/hypertensionaha.108.109801 .CrossRef PubMed
9.Davidov M, Kakaviatos N, Finnerty Jr FA. Antihypertensive properties of furosemide. Circulation. 1967;36(1):125–35.CrossRef PubMed
10.Healy JJ, McKenna TJ, Canning BS, Brien TG, Duffy GJ, Muldowney FP. Body composition changes in hypertensive subjects on long-term oral diuretic therapy. Br Med J. 1970;1(5698):716–9.CrossRef PubMed PubMedCentral
11.Orlov SN, Tremblay J, Hamet P. NKCC1 and hypertension: a novel therapeutic target involved in the regulation of vascular tone and renal function. Curr Opin Nephrol Hypertens. 2010;19(2):163–8. doi:10.1097/MNH.0b013e3283360a46 .CrossRef PubMed
12.Fortuno A, Muniz P, Ravassa S, Rodriguez JA, Fortuno MA, Zalba G, et al. Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension. 1999;34(1):138–43.CrossRef PubMed
13.Hocherl K, Kees F, Kramer BK, Kurtz A. Cyclosporine A attenuates the natriuretic action of loop diuretics by inhibition of renal COX-2 expression. Kidney Int. 2004;65(6):2071–80. doi:10.1111/j.1523-1755.2004.00627.x .CrossRef PubMed
14.Harris RC, Zhang MZ, Cheng HF. Cyclooxygenase-2 and the renal renin-angiotensin system. Acta Physiol Scand. 2004;181(4):543–7. doi:10.1111/j.1365-201X.2004.01329.x .CrossRef PubMed
15.Matzdorf C, Kurtz A, Hocherl K. COX-2 activity determines the level of renin expression but is dispensable for acute upregulation of renin expression in rat kidneys. Am J Physiol Ren Physiol. 2007;292(6):F1782–90. doi:10.1152/ajprenal.00513.2006 .CrossRef
16.•
Musini VM, Rezapour P, Wright JM, Bassett K, Jauca CD. Blood pressure-lowering efficacy of loop diuretics for primary hypertension. Cochrane Database Syst Rev. 2015;5, CD003825. doi:10.1002/14651858.CD003825.pub4 . Interesting review of antihypertensive effects of loop diuretics.PubMed
17.Wertheimer L, Finnerty Jr FA, Bercu BA, Hall RH. Furosemide in essential hypertension. A statistical analysis of three double-blind studies. Arch Intern Med. 1971;127(5):934–8.CrossRef PubMed
18.Achhammer I, Metz P. Low dose loop diuretics in essential hypertension. Experience with torasemide. Drugs. 1991;41 Suppl 3:80–91.CrossRef PubMed
19.Spannbrucker N, Achhammer I, Metz P, Glocke M. Comparative study on the antihypertensive efficacy of torasemide and indapamide in patients with essential hypertension. Arzneimittelforschung. 1988;38(1A):190–3.PubMed
20.Dupont AG, Schoors D, Six RO, Vanhaelst L. Antihypertensive efficacy of low dose torasemide in essential hypertension: a placebo-controlled study. J Hum Hypertens. 1988;2(4):265–8.PubMed
21.Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc Drugs Ther. 1993;7 Suppl 1:63–8.CrossRef PubMed
22.Brater DC. Clinical pharmacology of loop diuretics. Drugs. 1991;41 Suppl 3:14–22.CrossRef PubMed
23.Vasavada N, Saha C, Agarwal R. A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease. Kidney Int. 2003;64(2):632–40. doi:10.1046/j.1523-1755.2003.00124.x .CrossRef PubMed
24.Knauf H, Mutschler E. Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure. J Cardiovasc Pharmacol. 1995;26(3):394–400.CrossRef PubMed
25.Agarwal R, Sinha AD, Pappas MK, Ammous F. Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study. Am J Nephrol. 2014;39(2):171–82. doi:10.1159/000358603 .CrossRef PubMed
26.Broekhuysen J, Deger F, Douchamps J, Ducarne H, Herchuelz A. Torasemide, a new potent diuretic. Double-blind comparison with furosemide. Eur J Clin Pharmacol. 1986;31(Suppl):29–34.CrossRef PubMed
27.Dunn CJ, Fitton A, Brogden RN. Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs. 1995;49:121–42.CrossRef PubMed
28.Knauf H, Mutschler E. Clinical pharmacokinetics and pharmacodynamics of torasemide. Clin Pharmacokinet. 1998;34(1):1–24. doi:10.2165/00003088-199834010-00001 .CrossRef PubMed
29.Luft FC. Torasemide in the treatment of arterial hypertension. J Cardiovasc Pharmacol. 1993;22 Suppl 3:S32–9.CrossRef PubMed
30.Vlase H. Effectiveness of furosemide in uncontrolled hypertension in the elderly: role of renin profiling. Am J Hypertens. 2003;16(3):187–93. doi:10.1016/s0895-7061(02)03260-0 .CrossRef PubMed
31.Vadasz TA, Chadha DR. Experience with once-daily and twice-daily slow-release frusemide in hypertension. J Int Med Res. 1982;10(4):199–203.PubMed
32.Araoye MA, Chang MY, Khatri IM, Freis ED. Furosemide compared with hydrochlorothiazide. Long-term treatment of hypertension. JAMA. 1978;240(17):1863–6.CrossRef PubMed
33.Finnerty Jr FA, Maxwell MH, Lunn J, Moser M. Long-term effects of furosemide and hydrochlorothiazide in patients with essential hypertension a two-year comparison of efficacy and safety. Angiology. 1977;28(2):125–33.CrossRef PubMed
34.Valmin K, Hansen T. Treatment of benign essential hypertension: comparison of furosemide and hydrochlorothiazide. Eur J Clin Pharmacol. 1975;8(6):393–401.CrossRef PubMed
35.Ram CV, Garrett BN, Kaplan NM. Moderate sodium restriction and various diuretics in the treatment of hypertension. Arch Intern Med. 1981;141(8):1015–9.CrossRef PubMed
36.Anderson J, Godfrey BE, Hill DM, Munro-Faure AD, Sheldon J. A comparison of the effects of hydrochlorothiazide and of frusemide in the treatment of hypertensive patients. Q J Med. 1971;40:541–60.PubMed
37.Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension. 2002;39(5):982–8.CrossRef PubMed
38.Vaughan Jr ED, Laragh JH, Gavras I, Bühler FR, Gavras H, Brunner HR, et al. Volume factor in low and normal renin essential hypertension: treatment with either spironolactone or chlorthalidone. Am J Cardiol. 1973;32(4):523–32. doi:10.1016/S0002-9149(73)80044-X .CrossRef PubMed
39.•
Mann SJ, Ernst ME. Personalizing the diuretic treatment of hypertension: the need for more clinical and research attention. Curr Hypertens Rep. 2015;17(4):542. doi:10.1007/s11906-015-0542-4 . Review of subtleties of diuretic use in hypertension.CrossRef PubMed